Advertisement

Pfizer tops Q1 expectations, revises 2022 forecast

The coronavirus vaccine Comirnaty brought in more than $13 billion in sales

Agencies | Updated on: Tuesday, May 03, 2022, 07:44 PM IST

Analysts expected per-share earnings of $1.49 on about $24.1 billion in sales, according to FactSet.
/Representative image |
Analysts expected per-share earnings of $1.49 on about $24.1 billion in sales, according to FactSet. /Representative image |
Advertisement

Sales of Pfizer's COVID-19 vaccine and treatment pushed the drugmaker well past expectations in the first quarter, as profit grew 61per cent.

The coronavirus vaccine Comirnaty brought in more than $13 billion in sales, and the treatment Paxlovid added another $1.5 billion as company revenue swelled 77per cent, the company said Tuesday.

Pfizer posted adjusted earnings of $1.62 per share in the first quarter, on $25.66 billion in revenue.

Analysts expected per-share earnings of $1.49 on about $24.1 billion in sales, according to FactSet.

Pfizer Inc., based in New York, also revised its 2022 earnings forecast to reflect an accounting policy change. It now expects adjusted earnings of $6.25 to $6.45 per share.

That's down from its previous forecast for $6.35 to $6.55 per share.

Analysts forecast earnings of $7.14 per share.

Shares ticked slightly higher before the opening bell Thursday.

(With inputs from PTI)

(To receive our E-paper on whatsapp daily, please click here. To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

Published on: Tuesday, May 03, 2022, 07:44 PM IST